Shigella toxin is a multimeric protein consisting of one A subunit (M,., 32,000) and five B subunits (Mr, 6,500) (1). It is produced by all species of the genus and is believed to play an important role in pathogenesis of clinical shigellosis (2). Shigella toxin is particularly interesting because several different biological effects are mediated by the same highly purified molecule (1, 3). For example, it causes fluid secretion when placed in the lumen of rabbit small intestine (enterotoxicity) (2), but results in delayed limb paralysis and then death if administered parenterally in the same species (neurotoxicity) (4). When directly injected into the vagus nerve trunk of rats, shigella toxin travels in retrograde fashion via the axon to the neuronal cell body, causing dissolution of Nissl substance and death of the neuron (neuronotoxicity) (5). It is also lethal to certain cell culture lines (cytotoxicity) due to inhibition of protein synthesis (6, 7). The latter effect has also been shown in cell-free protein synthesis systems (8). The mechanism appears to be an irreversible and probably catalytic inactivation of the 60 S ribosomal subunit by the toxin A subunit (9).
this statement includes: (a) the loss of sensitivity to toxin when HeLa cells are treated with tunicamycin (10) , an inhibitor of N-linked glycoprotein synthesis; (b) competitive inhibition of the cytotoxic response of HeLa cells when incubated with GlcNAc-specific lectins (10, 11) or oligomeric/31---~4-1inked GIcNAc (11) ; (c) inhibition of toxin binding and bioactivity in HeLa cells by B subunit-specific antibodies but not by A subunit-specific antibodies (1); and (d) the demonstration that renatured, purified B subunits bind to the HeLa cell surface and compete for binding of the holotoxin, whereas purified A subunit neither binds nor inhibits binding of the intact toxin (Donohue-Rolfe, A., and G. T. Keusch, manuscript in preparation).
Overnight incubation of cells in the presence of tunicamycin, which completely inhibits the cytotoxic response to 100 50% tissue culture lethal doses (TCs0) of toxin, reduces toxin binding by only 55-60% (10) . We have therefore suggested that a second toxin-binding site is present on HeLa cells and that this site is not involved in the cytotoxic response (10) . This is the probable explanation for our previous observations (2) and those of Eiklid and Olsnes (7) that the response of HeLa cell lines of widely differing sensitivity to toxin fails to correlate with the number of receptors present. Preliminary experiments have indicated that this second HeLa cell receptor is a glycolipid, similar to a chloroform/methanol soluble toxin-binding site on rabbit jejunal brush border membranes (2, 12) . The present study was undertaken to isolate and identify this glycolipid from both HeLa cells and rabbit intestinal epithelial cells.
Materials and Methods
Materials. Casamino acids were obtained from Difco Laboratories Inc., Detroit, MI. Blue Sepharose CL-6B, polybuffer exchanger 94 and polybuffer 96, and DEAE-Sephadex were purchased from Pharmacia Fine Chemicals, Piscataway, NJ. BioGel P-60 was obtained from Bio-Rad Laboratories, Richmond, CA. Chloramine T, Na metabisulfite, rabbit hemoglobin, and BSA were from Sigma Chemical Co., St. Louis, MO. NaJ25I (17.4 Ci/mg) and Bolton Hunter reagent were purchased from New England Nuclear, Boston, MA. All tissue culture media were from Gibco Laboratories, Grand Island, NY. Highperformance thin-layer chromatography (HPTLC) plates were purchased from either Merck, Darmstadt, West Germany, or J.T. Baker Chemical Co., Phillipsburg, NJ. Primuline was obtained from Aldrich Chemical Co., Milwaukee, WI. Soluble Gal~l---~4Gal was purchased from Socker-Bolaget Fine Chemicals, Arlov, Sweden.
Toxin Production. Shigella toxin was produced and purified in three steps from Shigella dysenteriae 1, strain 60 R, as previously described (1). The pure toxin was lyophilized in ammonium bicarbonate and stored at -70°C. The A and B subunits were dissociated in 5% formic acid and isolated by chromatography on BioGel P-60, as previously reported (1) . Toxin or isolated A or B subunits were labeled with Jz5I by a modification of the chloramine T procedure (1) .
Antibodies. Rabbit polyclonal (Rab) and mouse monoclonal A and B subunit-specific antibodies (designated 5B2 and 4D3, respectively) have been described before (I). Rat lgM mAb to Gb~ (globotriaosylceramide) 2 and an IgG~ mouse mAb raised against Ill :~ FucnLc4, designated 38.13 and FH3, respectively, were prepared and characterized as previously reported (13, 14) . For some experiments, these antibodies were iodinated by the Bolton Hunter method (15) .
Growth of HeLa Cells and Assay of Shigella Cytotoxicity. HeLa cells (CCL-2; American Type Culture Collection, Rockville, MD) were grown at 37°C in McCoys 5a (modified) Glycolipids are abbreviated according to the recommendations of the Nomenclature Committee of the International Union of Pure and Applied Chemistry. medium containing I0% FCS (16) . 50 ml of packed HeLa ceils were obtained for lipid studies after passaging cells to multiple 150-ram Petri dishes. Cells were harvested by scraping with a rubber policeman, centrifuged at low speed, and the pellet was frozen until used. Toxin was assayed with a previously described cytolethal assay using tteLa cells in rnonolayer culture in microtiter plates (16) .
Extraction and Purification of Lipids. The total lipid was extracted from packed HeLa cells or rabbit jejunal mucosal scrapings in isopropanol/hexane/water (55: 25:20) and dried in a rotary evaporator (17) . A Folch partition was performed in chloroform/methanol (2:1) (18). The upper phase gtycolipids were then fractionated by DEAE-Sephadex chromatography to obtain the upper neutral (UN) glycolipids, while leaving gangliosides still bound to the column (19) . The lower phase (LP) glycolipids from the Folch partition were acetylated, purified on a Florisil column, and deacetylated (20) . Authentic Gb3 standard was purified from human erythrocyte membranes by HPLC, as previously described (21) . IsoGb3 was prepared from rat globoisotetraosylceramide by enzymatic hydrolysis with/3-galactosidase (22) .
High-Performance Thin-Layer Chromatography. Gb3 was purified from LP glycolipids from HeLa cells and rabbit jejunal mucosa by preparative HPTLC, as previously described, using the solvent system chloroform/methanol/water (60:35:7) and detected by staining with primuline (13) . The upper (U) and lower (L) bands of the Gb3 doublet were separated, isolated for use in some studies, and designated Gb3-U and Gb3-L, respectively. The specificity of the toxin was tested by direct binding studies to glycolipids separated on HPTLC SI plates (J.T. Baker Chemical Co.) in chloroform/methanol/water (50:40:10) containing 0.02% CaCI., (final concentration). Dried plates were soaked for 1 min in 0.5% polyisobutylmethacrylate in acetone, dried, sprayed with 5% BSA in PBS, and then soaked in the same solution for 2 h (13). Finally, the plates were incubated at 4°C for 4 h in PBS/0.1% BSA containing 2 x 105 cpm/ml of 12~I-toxin (sp act ~5 X 104 cpm/ng), washed thoroughly, dried, and autoradiograms were prepared (XAR-5 film, Eastman Kodak Co., Rochester, NY). To visualize the separated glycolipids, plates were then sprayed with 0.5% orcinol in 10% aqueous HeSO4 and heated to 100°C.
Solid Phase Binding Studies. Five parts of lecithin and three parts of cholesterol were mixed with one part (w/w) of purified glycolipid in absolute ethanol to achieve a concentration of 4 mg glycolipid per ml. Glycolipids used included LacCer, iGb3, Gb~, Gb4, nLc6, and Gg4. 50 #1 of this mixture was added to the first well and serial twofold dilutions were made with absolute ethanol in 96-well, soft fiat-bottomed microtiter plates. The plates were dried at 37°C for 1 h and then incubated with PBS/5% BSA for 2 h to block nonspecific binding sites. Blocking solution was then replaced with either iodinated toxin or purified A or B subunits in 30 ml of PBS/0.1% BSA for 4 h at 4°C. Wells were washed five times with PBS, cut with a hot wire, and radioactivity was counted in a gamma spectrometer.
In some experiments, liposomes were prepared by sonication of the same lecithin/cholesterol/glycolipid mixtures in PBS. HeLa cells were grown to near confluency in quadruplicate tissue culture microtiter plates and then incubted with 5% BSA in PBS for 1 h. Plates were chilled to 4°C and serial dilutions of the liposomes were added so that the first well contained 500 ng of glycolipid. Control plates were identically prepared except for the omission of liposomes. J2r'I-toxin (105 cpm) was then added. After 2 h of incubation with shaking at 4°C, all plates were washed five times in PBS. One set of plates was used to measure bound radioactivity in a gamma scintillation counter. The second set of plates was inoculated with 200 #1 of fresh McCoy's medium per well, incubated at 37 °C overnight, and cytotoxicity was measured as described above. Solid-Phase Binding Studies. Fig. 2 shows the binding of 125I-toxin to glycolipid-coated microtiter plates. Toxin bound to purified erythrocyte Gb3 and to the isolated upper and lower bands of the Gb~ doublet (Gb3-U and Gb3-L, respectively) in both H e L a cell and rabbit jejunal LP glycolipids. T h e extent of binding to Gb3-U and Gb~-L lipids from each tissue was similar, and was -5 0 -fold greater to Gb~ than to LacCer, as estimated from the titration curve shown in Fig. 2 . T h e r e was no detectable binding to iGb3, Gb4, nLc4, or nLc6.
Results

HPTLC of HeLa Cell and Rabbit Jejunal Lipids and Toxin Binding.
Consistent results were observed when glycolipid-containing liposomes were used to compete for toxin binding to H e L a cell monolayers (Fig. 3) . Thus, purified Gb3 was a highly effective inhibitor, whether obtained from erythrocyte membranes or from H e L a cells or rabbit jejunum. Isolated Gb3-U and Gb3-L front H e L a and rabbit LP glycolipid extracts were similar in ability to inhibit binding of toxin to H e L a cell monolayers. Liposomes containing LacCer, nLc6, or IVZFucnLc4 were inactive in these experiments. In addition, neither soluble cbitotriose (1 mg/ml) nor soluble Gai~l--*4Gal (1 mg/ml), the terminal disaccharide of Gb3, inhibited toxin binding (data not shown).
T h e effect of anti-glycolipid and anti-toxin antibodies on toxin binding to Gb3 from the different tissues was then studied (Fig. 4) . In contrast to antibody FH3, which was raised against an unrelated glycolipid antigen and had no discernible is probably related to its inability to bind strongly to Gb3-coated plates, since only 0.5% of the input counts of 125I-labeled antibody were observed to bind (data not shown).
Binding of Isolated A and B Subunits to Gb~. Fig. 5 shows the binding of toxin subunits to glycoprotein-coated microtiter plates. ~z'~I-B subunit bound to Gh3 (A) but not to LacCer (&), whereas the A subunit failed to bind to either glycolipid (O e). Fig. 6 shows competitive inhibition of binding of intact ]zsItoxin to Gb~ by unlabeled shigella toxin or isolated A and B subunits. Both intact toxin (I--1) and B subunit (A) were good competitive inhibitors, whereas A subunit (©) or cholera toxin (m) were not. Reciprocal Dilution of Competing Molecule FIGURE 6. Inhibition of binding of ]251-shigella toxin to Ob~-coated microtiter plates by unlabeled shigella toxin (V'l) or isolated A or B subunits (© and/x, respectively) and cholera toxin (I). The initial concentration of the competing molecule represents a 100-fold molar excess in relation to iodinated holotoxin. Additional experiments were then performed to determine the effect of subunit-specific antibodies on the binding of intact toxin or isolated A and B subunits to Gba-coated microtiter plates (Fig. 7) . The binding of holotoxin and B subunit (Fig. 7 , A and C, respectively) was inhibited by the B subunit-specific antibody, 4D3 (@), but not by the A subunit-specific antibody, 5B2 (O). In contrast, the limited binding of the A subunit (panel B) was inhibited by the Aspecific antibody but not by the B-specific antibody (note the 10-fold decrease in scale of the ordinate). These data show that the binding of the A subunit to Gb3 was not due to contamination of the A subunit preparation by the B subunit.
Competitive Inhibition of the Cytotoxic Response of HeLa Cells to Shigella Toxin by Glycolipid-Containing Liposomes and Soluble Oligosaccharides.
In parallel with the competitive binding studies shown in Fig. 3 , the cytotoxic response of HeLa cells was determined in the presence of serial dilutions of glycolipid-containing iiposomes (Table I) . Neither Gb.s (whether obtained from erythrocytes, HeLa cells, or rabbit jejunum) nor non-toxin-binding glycolipids inhibited cytotoxicity, although all Gb3 liposomes inhibited binding of toxin to HeLa cells by >90% (Fig.  3) . The soluble terminal Gal~l-*4Gal disaccharide of Gb3 also failed to affect toxin activity in HeLa monolayers, whereas chitotriose had a marked inhibitory effect (Table II) . Discussion In this paper we have shown that shigella toxin can specifically bind to a glycolipid present in both rabbit jejunal mucosa and HeLa cells. This glycolipid was identified as Gb3 (giobotriaosylceramide) by comparison of its mobility on HPTLC with that of authentic Gb3 isolated from human type B erythrocyte membranes. Rabbit jejunal or HeLa cell Gb3 and purified Gb3 derived from human type B erythrocytes all showed similar toxin binding capacity. Moreover, when these sources of Gb3 were incorporated into liposomes they possessed similar ability to competitively inhibit the binding of toxin to HeLa monolayers. Toxin also bound to a second band in the glyco|ipid extracts of erythrocyte membranes in the position at which Gb4 and aOH-Gb~ (Gb3 containing ~-hydroxylated fatty acid and phytosphingosine) are known to comigrate. Since toxin was unable to bind to purified Gb4 in solid phase binding studies it is likely that the minor band detected is aOH-Gb3. A third toxin-binding band was identified in type B human erythrocyte extracts, which is probably the proposed P~ erythrocyte antigen structure, IVaGalnLc4 (23) . This has a Gal o~1---~4 linked to riLE4 so that it possesses the same terminal Galal---*4Gal disaccharide structure as Gb3, but linked /31---~4 to GicNac instead of Glc. As this glycolipid was not available for further study, experiments to confirm this interpretation were not possible. The important observation, however, is the identification of the Gb3 glycolipid-binding site for shigella toxin in rabbit jejunum and HeLa cells. This is consistent with preliminary studies of other investigators, who have reported that the specific disaccharide, Galc~l---->4Gal coupled to BSA, inhibits the binding of shigella toxin to HeLa cells (24) .
Our data show the fine specificity of the binding for Gb3, since neither iGb3 (which is identical to Gb3 except that the Gal-Gal disaccharide is linked c~1---~3 instead of al---~4) nor LacCer (which differs from Gb~ in the deletion of the terminal galactose residue) or Gb4 (which has a terminal GalNAc linked/31-->3 to Gb3) were able to bind shigella toxin. Since soluble Galal--->4Gal failed to competitively inhibit binding of toxin to HeLa cells, our evidence indicates that receptor activity for shigella toxin requires terminal Galo~l---~4Gal linked to another residue (either Glc or GIcNAc from the studies described here). It is also clear that the binding of toxin to Gb~ is via the toxin B subunit. Purified B subunit bound to Gb:~ but not to LacCer, whereas purified A subunit bound to neither glycolipid. This is consistent with our observation that only the holotoxin or the B subunit, but not the A subunit or cholera toxin, inhibited binding of intact ~z'~I-holotoxin to Gb3-coated microtiter plates. A third piece of evidence is that binding of toxin or B subunit to Gbs was completely inhibited by a B subunit-specific mAb, whereas an A subunit-specific mAb had no effect.
The Gb3 toxin-binding component was detected in HeLa cells. Moreover, the binding of shigella toxin to these cells was competitively reduced by >90% in the presence of Gb3 incorporated into liposomes. Nevertheless, we found no evidence that binding to Gb3 was responsible for the HeLa cell cytotoxicity of shigella toxin, since the addition of Gb3-containing liposomes failed to diminish the cytotoxic response of HeLa monolayers to toxin. This is not entirely surprising because we have previously presented evidence that cytotoxicity is mediated by a tunicamycin-sensitive glycoprotein containing GlcNAc linked /31---4 to GlcNAc (10) . The present studies provide additional data to support this, as shown by the competitive inhibition of toxicity by trimeric/31---~4-1inked GlcNAc (chitotriose). We have also found that overnight incubation of HeLa cells in the presence of a sufficient concentration of tunicamycin to completely abrogate the response to 100 TC~0 doses of toxin, reduces specific binding of toxin by only 55-60% (10), and does not appear to diminish the amount of the extractable glycolipid toxin-binding component of HeLa cells (present study). This residual binding can now be explained, at least in part, by the tunicamycin-resistant Gb:~ receptor. That this is distinct from a glycoprotein cytotoxic receptor is also shown by the observation that chitotriose inhibited the toxicity of shigella toxin for HeLa cells but not its binding to Gb3-coated microtiter plates. It is most interesting to note that while toxin binding to both receptors appears to be via the same toxin B subunit, as indicated by studies with purified subunits and subunitspecific mAbs, the glycoprotein and glycolipid binding sites exhibit distinctive sugar specificities (GIcNAc/31---->4GIcNAc-and Galc~l---~4Gai/31---~4 Glc or GlcNAc, respectively). We do not at present know how many different functional domains are present on the M,. 6 ,500 B subunit peptide, nor whether the B subunit-specific monoclonal, 4D3, recognizes more than one domain. We believe a more likely hypothesis is that 4D3 directly binds to one binding domain and sterically inhibits, but does not bind to, a second domain. Thus we propose a novel mechanism to explain the diverse effects of toxin that involves two distinct sugar-specific binding sites on the same small peptide that mediate the different biological activities. More data are certainly needed to reach a firm conclusion about this.
Rabbit jejunum responds in vivo to binding of toxin to the brush border surface by net secretion of isotonic fluid, but in contrast to the HeLa cell does not exhibit any histologically demonstrable cytotoxic response (25) . Preliminary studies with purified rabbit jejunal microvillus membranes (MVM) have shown a single class of binding site for toxin (26, 27) , and the present study indicates that this is Gb:~. Since Gb3 apparently does not mediate toxin effects in HeLa cells, the obvious question is whether or not binding to gut Gb3 initiates the fluid secretory response of rabbit small bowel. We cannot completely answer this question now, but other preliminary observations from our laboratory are consistent with such a role. We have reported that the appearance of Gb~ in rabbit jejunum is developmentally regulated in the New Zealand white rabbit (12) . Thus, animals younger than 16 d (and responsive to cholera toxin) do not secrete fluid when shigella toxin is placed in ligated small bowel loops (27) . However, a consistently positive fluid response occurs in animals older than 18 d when Gb~ becomes detectable in jejunal MVM, and binding of 125I-toxin to MVM is also demonstrable. While these results do not prove the physiological relevance of the Gb3 receptor, the data certainly suggest that binding to Gb3 in rabbit gut is coupled to a fluid secretory process. We presume that we cannot show any effect of toxin binding to HeLa cell Gb3 because HeLa cells are not secretory cells.
Gb:~ is also the determinant of the pk blood group antigen (28) . The Galc~l---~ 4Gal disaccharide of pk, whether terminal as in Gb3 or internal as in Gb4, is recognized by the GaI-Gal pilus of uropathogenic Escherichia coli (29) (30) (31) . This structure, also termed P pilus (after the P blood group system) or PAP pilus (for pyelonephritis-associated pilus), has been shown to be a virulence determinant of pill-positive E. coli strains, since it allows recognition and binding to renal epithelial membrane glycosphingolipids containing Galcd---~4Gal (32, 33) . Progress towards developing a vaccine for these strains of E. coli based on immunization with Gal-Gal pill or synthetic Gal-Gal has been reported (33, 34) . The common Gb~ receptor for shigella toxin and Gal-Gal positive uropathogenic E. coli suggests homology between domains of the shigella toxin B subunit and the Gal-Gal pilus. It is therefore possible that antitoxin antibodies might be generated by immunization with a Gal-Gal pilus vaccine. This might prove to be of practical use if immunization with receptor analogues fails to significantly block toxin activity, as already observed with the anti-Gb3 mAb used in these studies. It would be most interesting if a Gal-Gal pilus vaccine generated both antipilus and antitoxin antibodies to induce simultaneous resistance to pyelonephritis and shigellosis. Summary A glycolipid that specifically binds shigella toxin was isolated from both HeLa cells and rabbit jejunal mucosa and identified as globotriaosyiceramide (Gb~) by its identical mobility on HPTLC to authentic erythrocyte Gb3. Toxin also bound to a band tentatively identified as o~-hydroxylated Gb3. In addition, toxin bound to Pl antigen present in group B human erythrocyte glycolipid extracts. The common feature of the three binding glycolipids is a terminal Galal---~4Gal disaccharide linked/31---4 to either Glc or GIcNAc. Globoisotriaosylceramide, which differs from Gb3 only in possessing a Galo~l--*3Gal terminal disaccharide, and LacCer, which lacks the terminal Gal residue of Gb3, were incapable of binding the toxin. Binding was shown to be mediated by the B subunit by the use of isolated toxin A and B subunits and monoclonal subunit-specific antibodies. Gb3-containing liposomes competitively inhibited the binding of toxin to HeLa cell monolayers but did not inhibit toxin-induced cytotoxicity.
These studies show an identical carbohydrate-specific glycolipid receptor for shigella toxin in gut and in HeLa cells. The toxin B subunit that mediates this binding has also been shown to recognize a glycoprotein receptor with different sugar specificity. Thus, we have demonstrated that the same small (Mr 6,500) B subunit polypeptide has two distinctive carbohydrate-specific binding sites. The Galo~l---~4Gal disaccharide of the glycolipid toxin receptor is also recognized by the Gal-Gal pilus of uropathogenic E. coli. This suggests the possibility that the pilus and toxin B subunit contain homologous sequences. If this is true, it may be possible to use the purified Gai-Gal pilus to produce toxin-neutralizing antibodies.
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